Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension

Canadian Journal of Ophthalmology

Volumn 42, Issue 1, 2007, Pages 75-81

  Harasymowycz, Paul ^a   Hutnik, Cindy M L ^b   Nicolela, Marcelo ^c   Stewart, William C ^d  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Ivey Eye Institute   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d Pharmaceutical Research Network LLC   (Canada)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Timolol

Indexed keywords

LATANOPROST; TIMOLOL MALEATE;

ABNORMAL SENSATION; ADULT; ANXIETY DISORDER; ARTICLE; BLEPHARITIS; BRADYCARDIA; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONFUSION; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRY EYE; ERYTHEMA; EYE DISCHARGE; EYELID EDEMA; FEMALE; FOREIGN BODY SENSATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING DISORDER; HEART DISEASE; HEART INFARCTION; HUMAN; HYPEREMIA; INFECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NIGHTMARE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; SKIN DISCOLORATION; SKIN DISEASE; SLIT LAMP; SUPERFICIAL PUNCTATE KERATITIS; TIBIA FRACTURE; TREMOR; URETER OBSTRUCTION; VASCULAR DISEASE; VISUAL ACUITY;

EID: 33947155860     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1139/I06-096     Document Type: Article

References (31)

1. Patterson C. Screening for visual impairment in the elderly. In: Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa, Ont: Health Canada; 1994:932-42.
2. American Academy of Ophthalmology. Preferred Practice Pattern for Primary Open-Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2005.
3. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-52.
4. Camras CB, United States Latanoprost Study Group. Comparison of latanoprost and timolol in subjects with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
5. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-32.
6. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003;2:463-5.
7. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104.
8. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-90.
9. Sihota R, Saxena R, Agarwal HC, Pandey RM, Gulati V. Peak pressures: crossover study of timolol and latanoprost. Eur J Ophthalmol 2003;13:546-52.
10. Asrani S, Zeimer R, Wilensky J. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42.
11. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35.
12. Rouland JF, Morel-Mandrino P, Elena PP. Timolol 0.1% gel (Nyogel) 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 2002;216:449-54.
13. Shedden A, Laurence J, Tipping R, Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 2001;23:440-50.
14. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily Vs. Timolol gel in treating elevated TOP. J Glaucoma 1998;7:402-7.
15. Larsson L-I. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in subjects with ocular hypertension. Ophthalmology 2001;108:1439-44.
16. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM; Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49(suppl 1):S26-35.
17. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. London, UK: Chapman & Hall; 1989.
18. McCannel CA, Heinrich SR, Brubaker RE Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol 1992;230:518-20.
19. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985;26:1315-9.
20. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73.
21. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999;8:24-30.
22. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol 1998;126:390-9.
23. Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiendy controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000;84:181-5.
24. Zimmerman TJ, Stewart WC, Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405-15.
25. Bron AM, Denis P, Nordmann JP, Rouland JF, Sellem E, Johansson M. Additive IOP-reducing effect of latanoprost in patients insufficiendy controlled on timolol. Acta Ophthalmol Scand 2001;79:289-93.
26. Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22.
27. Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. J Glaucoma 2001;10:316-24.
28. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9.
29. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902.
30. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 1999;128:692-6.
31. Ravinet E, Mermoud A, Brignoli R. Four years later: a clinical update on latanoprost. Eur J Ophthalmol 2003;13:162-75.